Comparative analysis of the quality of life of heart failure patients in South Western Nigeria

A. C. Mbakwem, F. O. Aina, C. E. Amadi, A. A. Akinbode, J. Mokwunyei

Department of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria.
Department of Medicine, College of Medicine, University of Lagos, Lagos, Nigeria..
Department of Medicine, Lagos University Teaching Hospital, Lagos, Nigeria..
Department of Psychiatry, College of Medicine, University of Lagos, Lagos, Nigeria.
Department of Psychiatry, College of Medicine, University of Lagos, Lagos, Nigeria..

DOI: 10.4236/wjcd.2013.31A021                

Abstract

Background: Heart failure (HF) is a common, chronic clinical syndrome with appreciable impact on both prognosis and lifestyle of patients. Two main aims of management include preventing disease progression and improving quality of life (QoL). Not much work has been done in this area in Sub-Saharan Africa and most of the available disease specific instruments were developed using the Caucasian population. Aim: We therefore evaluated the QoL of stable HF patients attending the cardiology clinic of the Lagos University Teaching Hospital using a disease specific instrument, Kansas City Cardiomyopathy Questionnaire (KCCQ) and a generic one, the WHOQOL- BREF. Method: Consenting, stable HF patient were recruited from the cardiology clinic of the Lagos University Teaching Hospital. Relevant clinical data and echocardiographic parameters were retrieved from their clinical notes and the subjects filled out the questionnaires, the KCCQ and the WHOQOL-BREF. The QoL and four main domains in the WHOQOL- BREF were compared with scores on the KCCQ for relationships. Result: Data set of 190 patients was analysed. There were 91 (47.9%) males and 99 (52.1%) females with a mean age 51.90 ± 13.21 yrs. Only 52 (27.4%) had college education and 143 (75.2%) had very poor personal resources. About 104 (54.7%) were paying their medical bills themselves. The mean QoL score using the KCCQ score was 59.61 ± 23.80. With The KCCQ, 6.9% felt their QoL was poor and 20% felt it was fair while 11.6% and 20.5% felt their QoL was poor and fair respectively with the WHOQOL-BREF. There was positive correlation, p < 0.0001, between the KCCQ QoL and WHO-BREF QoL scores and the four domains assessed; physical health, psychological, social relationships, environment. Conclusion: Over 25% of HF patients in our environment have unacceptable levels of quality of life which has to be addressed in their management. The generic WHOQOL-BREF would suffice in our environment if the specific HFQoL instruments are not available.

Keywords

Comparative; Quality of Life; Heart Failure; South Western Nigeria

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Lloyd-Jones, D., Adams, R., Carnethon, M., et al. (2009) Heart disease and stroke statistics—2009 update: A report of the American Heart Association Statistics Committee and stroke statistics subcommittee. Circulation, 119, e21- e181. doi:10.1161/CIRCULATIONAHA.108.191261
[2]	Mosterd, A. and Hoes, A.W. (2007) Clinical epidemiology of heart failure. Heart, 93, 1137-1146. doi:10.1136/hrt.2003.025270
[3]	Task force for the diagnosis and treatment of acute and chronic heart failure (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 33, 1787-1847. doi:10.1093/eurheartj/ehs104
[4]	Feinstein, A.R., Fisher, M.B. and Pigeon, J.G. (1989) Changes in dyspnoea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. American Journal of Cardiology, 64, 50-55. doi:10.1016/0002-9149(89)90652-8
[5]	Guyatt, G.H., Thompson, P.J., Berman, L.B., Sullivan, M.J., Townsend, M., Jones, N.L. and Pugsley, S.O. (1985) How should we measure function in patients with chronic heart and lung disease. Journal of Chronic Diseases, 18, 517-524. doi:10.1016/0021-9681(85)90035-9
[6]	Ekman, I., Cleland, J.G., Andersson, B. and Swerdberg, K. (2005) Exploring symptoms in chronic heart failure. European Journal of Heart Failure, 7, 699-703. doi:10.1016/j.ejheart.2005.07.003
[7]	Packer, M., Narahara, K.A., Elkayam, U., Sullivan, J.M. and Hampton, J.R. (1993) Double-blind, placebo controlled study of flosequinan in patients with chronic heart failure. Principal investigators of the REFLECT study. Journal of the American College of Cardiology, 22, 65-72. doi:10.1016/0735-1097(93)90816-J
[8]	Cowley, A.J., Stainer, K., Wynne, R.D., Rowley, J.M. and Hampton, J.R. (1989)Comparison of the effects of captopril and enoximone in patients with severe heart failure: A placebo-controlled double-blind study. International Journal of Cardiology, 24, 311-316. doi:10.1016/0167-5273(89)90010-7
[9]	Tate, C.W., III, Robertson, A.D., Zolty, R., Shakar, S.F., Lidenfield, J., Wolfel, E., Bristow, M.R. and Lowes, B.D. (2007) Quality of life and prognosis in heart failure: Result of the Beta-Blocker Evaluation survival trial (BEST). Journal of Cardiac Failure, 13, 732-737. doi:10.1016/j.cardfail.2007.07.001
[10]	Bowling, A. (1995) What things are important in people’s lives? A survey of public’s judgement to inform scales of health related quality of life. Social Science & Medicine, 41, 1447-1462. doi:10.1016/0277-9536(95)00113-L
[11]	Cella, D.F. and Tulsky, D.S. (1990) Measuring quality of life today: Methodological aspects. Oncology, 4, 29-38.
[12]	World Health Organization (19-22 June 1946) Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference. New York.
[13]	Heart Failure Guideline panel (1994) Heart failure: Evaluation and care of patients with left ventricular dysfunction. AHCPR Publication, Silver Spring.
[14]	Konstan, V., Salem, D., Pouluer, H., Kostis, J., Gorkin, L., Shumaker, S., et al. (1996) Baseline quality of life as a predictor of mortality and hospitalisation in 5025 pateints with congestive heart failure. American Journal of Cardiology, 78, 890-895. doi:10.1016/S0002-9149(96)00463-8
[15]	Soto, G.E., Jones, P., Weintraub, W.S., Krumholz, H.M. and Spertus, J.A. (2004) Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation, 110, 546-551. doi:10.1161/01.CIR.0000136991.85540.A9
[16]	Green, P.C., Porter, C.B., Bresnahan, D.R. and Spertus, J.A. (200) Development and evaluation of the Kansas City cardiomyopathy questionnaire: A new health status measure for heart failure. Journal of the American College of Cardiology, 35, 1245-1255. doi:10.1016/S0735-1097(00)00531-3
[17]	Rector, T.S., Kubo, S.H. and Cohn, J.N. (1987) Patient’s self-assessment of their congestive heart failure: Content, reliability and validity of a new measure: The Minnesota living with heart failure questionnaire. Heart Failure, 3, 198-219.
[18]	Colluci, W.S., Packer, M., Bristow, M.R., Gilbert, E.M., Cohn, J.N., Fowler, M.B., et al. (1996) Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation, 94, 2800-2806. doi:10.1161/01.CIR.94.11.2800
[19]	Bristow, M.R., Gilbert, E.M., Abraham, W.T., Adams, K.F., Fowler, M.B., Hershberger, R.E., et al. (1996) Congestive heart failure/myocardial disease: Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation, 94, 2807-2816. doi:10.1161/01.CIR.94.11.2807
[20]	The World Health Orgainisation Quality of Life (WHO- QOL). http//www.who.int/evidence/assessmentinstrument/qol/q11. htm.
[21]	McHorney, C., Ware, J. and Raczek, A. (1993) The MOSitem short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31, 247-263. doi:10.1097/00005650-199303000-00006
[22]	Berry, C. and McMurray, J. (1996) A review of quality- of-life evaluations in patients with congestive heart failure. American Journal of Cardiology, 78, 890-895. doi:10.1016/S0002-9149(96)00463-8
[23]	Hobbs, F.D.R., Kengre, J.E., Roalife, A.K., Davis, R.C., Hare, R. and Davies, M.K. (2002) Impact of heart failure and left ventricular systolic dysfunction on quality of life. A cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. European Heart Journal, 23, 1867-1876. doi:10.1053/euhj.2002.3255
[24]	Hjalmarson, A., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., et al. (2000) Effects of controlled-release metoprolol on total mortality, hospitalisations and well being in patients with heart failure: The Metoprolol CR/XL Randomised Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group, JAMA, 283, 1295-1302. doi:10.1001/jama.283.10.1295
[25]	Calvert, M.J., Free-mantle, N. and Cleland, J.G.F. (2005) The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study. European Journal of Heart Failure, 7, 243-251.
[26]	Mc Donagh, T.A., Blue, L., Clark, A.L., Dahlstrom, U., Ekman, L., Lainsack, M., McDonald, K., Ryder, M., Stromberg, A. and Jaarsma, T. (2011) European Society of Cardiology Heart Failure Association Standards for delivering heart failure care. European Journal of Heart Failure, 13, 235-241. doi:10.1093/eurjhf/hfq221
[27]	Lewis, E.F., Johnson, P.A., Johnson, W., Collins, C., Griffin, L. and Stevenson, L.W. (2001) Preferences for quality of life or survival expressed by patients with heart failure. The Journal of Heart and Lung Transplantation, 20, 1016-1024. doi:10.1016/S1053-2498(01)00298-4
[28]	Rector, T.S., Tscumperin, L.K., Kobo, S.H., Bank, A.J., Francis, G.S., McDonald, K.M., et al. (1995) Using the living with heart failure questionnaire to ascertain patients’ perspective on improvement of in quality of life versus risk of drug induced death. Journal of Cardiac Failure, 1, 201-206. doi:10.1016/1071-9164(95)90025-X
[29]	Witte, K.K. and Clark, A.L. (2007) Why does chronic heart failure cause breathlessness and fatigue? Progress in Cardiovascular Diseases, 49, 366-384. doi:10.1016/j.pcad.2006.10.003
[30]	Comin-Colt, J., Lainscak, M., Dickstein, K., Fillipatos, G.S., Johnson, P., Luscher, T.F., Mori, C., Willenheimer, R., Ponikowski, P. and Anker, S. (2013) The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the FAIR-HF study. European Heart Journal, 34, 30-38. doi:10.1093/eurheartj/ehr504
[31]	Hole, T., Grundtvig, M., Flonaes, B. and Westheim, A. (2010) Improved quality of life in Norwegian heart failure patients after follow-up in outpatient heart failure clinics: Results from the Norwegian heart failure registry. European Heart Journal, 12, 1247-1252. doi:10.1093/eurjhf/hfq156